title: DNA hypermethylation as a chemotherapy target.
abstract: Epigenetics refers to partially reversible, somatically inheritable, but DNA sequence-independent traits that modulate gene expression, chromatin structure, and cell functions such as cell cycle and apoptosis. DNA methylation is an example of a crucial epigenetic event; aberrant DNA methylation patterns are frequently found in human malignancies. DNA hypermethylation and the associated expression silencing of tumor suppressor genes represent a hallmark of neoplastic cells. The cancer methylome is highly disrupted, making DNA methylation an excellent target for anti-cancer therapies. Several small synthetic and natural molecules, are able to reverse the DNA hypermethylation through inhibition of DNA methyltransferase (DNMT). DNMT is the enzyme catalyzing the transfer of methyl groups to cytosines in genomic DNA. These reagents are studied intensively in cell cultures, animal models, and clinical trials for potential anti-cancer activities. It was found that accompanying DNA demethylation is a dramatic reactivation of the silenced genes and inhibition of cancer cell proliferation, promotion of cell apoptosis, or sensitization of cells to other chemotherapeutic reagents. During the last few decades, an increasing number of DNMT inhibitors (DNMTi) targeting DNA methylation have been developed to increase efficacy with reduced toxicity. This review provides an update on new findings on cancer epigenetic mechanisms, the development of new DNMTi, and their application in the clinical setting. Current challenges, potential solutions, and future directions concerning the development of DNMTi are also discussed in this review.
authors.affiliation: Cancer Center, First Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, China.
authors.forename: Juan
authors.initials: J
authors.lastname: Ren
authors.forename: Brahma N
authors.initials: BN
authors.lastname: Singh
authors.forename: Qiang
authors.initials: Q
authors.lastname: Huang
authors.forename: Zongfang
authors.initials: Z
authors.lastname: Li
authors.forename: Ya
authors.initials: Y
authors.lastname: Gao
authors.forename: Prachi
authors.initials: P
authors.lastname: Mishra
authors.forename: Yi L
authors.initials: YL
authors.lastname: Hwa
authors.forename: Jinping
authors.initials: J
authors.lastname: Li
authors.forename: Sean C
authors.initials: SC
authors.lastname: Dowdy
authors.forename: Shi-Wen
authors.initials: SW
authors.lastname: Jiang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017321:Clinical Trials, Phase I as Topic; D019175:DNA Methylation / Q000187:drug effects*; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D044127:Epigenesis, Genetic; D020868:Gene Silencing; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D015254:DNA Modification Methylases